Allarity Therapeutics vs Scienture
ALLR and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and SCNX compare
Scienture is the larger company, worth 8.8 times as much as Allarity Therapeutics ($123M against $13.9M).
Scienture scores higher on the StockData Score (3 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | SCNX |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $123M |
| Share price | $0.875 | $2.99 |
| Change, 1 year | −26.5% | −82.2% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | 1.41 | 1.07 |
| Employees | 8 | 8 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.9× | 1.9× (better) |
| Growth | ||
| Revenue growth, 5Y average | – | −52.1% |
| Profitability | ||
| Return on equity | −157% | −53.5% (better) |
| Return on invested capital | −957% | −47.3% (better) |
| Financial health | ||
| Debt / equity | 5.90 | – |
| Interest coverage | −10.1× (better) | −13.1× |
| Current ratio | 1.11 | 3.04 (better) |
| Altman Z-score | −6.64 | 0.31 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 8.1% | – |
| Held by insiders | 6.3% | 16.6% |
| Short interest, % of float | 1.5% | 0.34% |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.